MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial

We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received obinutuzumab (G) plus bendamustine (Benda) induction followed by G maintenance, or Benda in...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia 2020-02, Vol.34 (2), p.522-532
Main Authors: Pott, Christiane, Sehn, Laurie H., Belada, David, Gribben, John, Hoster, Eva, Kahl, Brad, Kehden, Britta, Nicolas-Virelizier, Emmanuelle, Spielewoy, Nathalie, Fingerle-Rowson, Guenter, Harbron, Chris, Mundt, Kirsten, Wassner-Fritsch, Elisabeth, Cheson, Bruce D.
Format: Article
Language:English
Subjects:
631/67/1990
692/700/1750
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bendamustine
Bendamustine Hydrochloride - administration & dosage
Biotechnology industry
Cancer Research
Critical Care Medicine
Female
Hematology
Humans
Immunotherapy
Intensive
Internal Medicine
Lymphoma
Lymphoma, Follicular - drug therapy
Lymphoma, Non-Hodgkin - drug therapy
Maintenance
Male
Medical colleges
Medicine
Medicine & Public Health
Middle Aged
Minimal residual disease
Monoclonal antibodies
Neoplasm, Residual - drug therapy
Non-Hodgkin's lymphomas
Oncology
Progression-Free Survival
Regrowth
Rituximab
Rituximab - administration & dosage
Survival
Targeted cancer therapy
Translocation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received obinutuzumab (G) plus bendamustine (Benda) induction followed by G maintenance, or Benda induction alone. Patients with a clonal marker (t[14;18] translocation and/or immunoglobulin heavy or light chain rearrangement) detected at study screening were assessed for MRD at mid-induction (MI), end of induction (EOI), and every 6–24 months post-EOI/discontinuation by real-time quantitative PCR. At MI, 41/52 (79%) patients receiving G-Benda were MRD-negative vs. 17/36 (47%) patients receiving Benda alone ( p  = 0.0029). At EOI, 54/63 (86%) patients receiving G-Benda were MRD-negative vs. 30/55 (55%) receiving Benda alone ( p  = 0.0002). MRD-negative patients at EOI had improved progression-free survival (HR, 0.33, 95% CI, 0.19–0.56, p  
ISSN:0887-6924
1476-5551
DOI:10.1038/s41375-019-0559-9